Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexchlorpheniramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 6/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 6/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 6/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 4/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 4/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | SCN1A | P35498 | 3/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 3/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | HRH2 | P25021 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorpheniramine SCHEMBL4314182 | 1.00 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Chlorpheniramine SCHEMBL20956397 | 1.00 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Chlorpheniramine SCHEMBL4220 | 1.00 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Chlorpheniramine SCHEMBL4219 | 1.00 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Chlorpheniramine SCHEMBL29687335 | 1.00 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Chlorpheniramine SCHEMBL5022351 | 0.99 | CHRM2 (0.97) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Chlorpheniramine SCHEMBL14879822 | 0.99 | CHRM2 (0.97) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Chlorpheniramine SCHEMBL506017 | 0.99 | CHRM2 (0.97) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Chlorpheniramine SCHEMBL10622596 | 0.99 | CHRM2 (0.97) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 | |
| Chlorpheniramine SCHEMBL14879823 | 0.99 | CHRM2 (0.97) | CHRM2SLC6A2SLC6A4HRH1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9124 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| WO-2025264260-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP TECHNOLOGIES, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| EP-4655809-A1 | QUANTUM DIPOLE BATTERY | Pronoia, Inc. (US) | 2025-12-03 | — | — | EP | claimed |
| WO-2025244529-A1 | DOSING REGIMEN OF AN EGFR BINDING AND/OR COMPLEMENT ACTIVATING ANTIBODY | MERUS N.V. (NL) | 2025-11-27 | — | — | WO | claimed |
| US-20250332088-A1 | SUSTAINED RELEASE COMPOSITIONS | RUBICON RES PRIVATE LIMITED (IN) | 2025-10-30 | — | — | US | claimed |
| US-12453712-B2 | Antitumoral use of cabazitaxel | SANOFI MATURE IP (FR) | 2025-10-28 | — | — | US | claimed |
| EP-4630401-A2 | CARBONIC ANHYDRASE ENZYME INHIBITORS AND METHODS OF USE THEREOF | Rutgers, the State University of New Jersey (US) | 2025-10-15 | — | — | EP | claimed |
| EP-4247331-B1 | ORODISPERSIBLE POWDER COMPOSITION COMPRISING AN ANTIHISTAMINE COMPOUND | BIOPHARMA SYNERGIES S L (ES) | 2025-10-08 | — | — | EP | claimed |
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| US-4996047-A | Sustained release drug-resin complexes | RICHARDSON-VICKS, INC. (US) | 1991-02-26 | — | — | US | claimed |
| EP-0367746-A2 | Sustained release drug-resin complexes | RICHARDSON-VICKS, INC. (US) | 1990-05-09 | — | — | EP | claimed |
| US-4840962-A | MIXTURE WITH ANTIHISTAMINE, DECONGESTANT AND/OR ANTITUSSIVE AGENT | ANALGESIC ASSOCIATES (US) | 1989-06-20 | — | — | US | claimed |
| US-4749720-A | ANALGESICS AND ANTIHISTAMINES | ANALGESIC ASSOCIATES (US) | 1988-06-07 | — | — | US | claimed |
| US-4749697-A | ADMINISTERING MIXTURES OF PIROXICAM, SUDOXICAM, OR ISOXICAM WITH ANTIHISTAMINE | ANALGESIC ASSOCIATES (US) | 1988-06-07 | — | — | US | claimed |
| US-4749723-A | ADMINISTERING MEFENAMIC ACID, SODIUM MECLOFENAMATE OR SALT WITH ANTIHISTAMINE | ANALGESIC ASSOCIATES (US) | 1988-06-07 | — | — | US | claimed |
| US-4749700-A | NASAL ADMINISTRATION LOWER DOSAGE | NASTECH PHARMACEUTICAL CO, INC. (US) | 1988-06-07 | — | — | US | claimed |
| US-4619934-A | AND ANTIHISTAMINE, DECONGESTANT, ANTITUSSIVE OR EXPECTORANT | ANALGESIC ASSOCIATES (US) | 1986-10-28 | — | — | US | claimed |
| EP-0180597-A1 | COUGH/COLD MIXTURES COMPRISING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS. | SUNSHINE ABRAHAM (US) | 1986-05-14 | — | — | EP | claimed |
| WO-1985004589-A1 | COUGH/COLD MIXTURES COMPRISING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | SUNSHINE ABRAHAM | 1985-10-24 | — | — | WO | claimed |